Congress funds research on cosmetics chemicals linked to reproductive harm

What it does

This bill directs the Department of Health and Human Services to award federal research grants studying how endocrine-disrupting chemicals in personal care products (cosmetics, shampoos, soaps, etc.) affect women's reproductive health, and to fund state-level investigation and public awareness programs on the same topic. The bill requires HHS to report findings to Congress every five years and recommend regulatory strategies to expand FDA oversight of these chemicals.

Why we flagged it

The bill's operative mechanism is straightforward: federal grant funding for research and state awareness programs on a specific reproductive health hazard. It is a research and education bill, not a regulatory change or industry carve-out.

What the text implies

• The bill's requirement that HHS recommend 'evidence-based or evidence-informed legislative or administrative strategies to increase the FDA's domain' to regulate endocrine-disrupting chemicals may eventually lead to stricter cosmetics ingredient rules, which could increase compliance costs for personal care product manufacturers and potentially reduce product availability or raise consumer prices.
• State-level investigation and awareness programs may create inconsistent regulatory expectations across states, potentially fragmenting the personal care product market if states adopt divergent standards based on grant-funded research.
• The five-year reporting cycle and ongoing grant structure create a long-term federal commitment to this research area, potentially establishing endocrine-disrupting chemicals as a permanent regulatory focus for the FDA and HHS.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill funds public health research and awareness on a documented reproductive health concern affecting all women, with no direct costs to citizens and potential long-term benefit from expanded regulatory knowledge and state-level education. The mapped stocks show regulatory exposure, indicating the bill may eventually lead to stricter cosmetics ingredient rules—a public health gain, not a cost to ordinary people.

Who stands to gain

• research institutions and universities (grant recipients)
• state health departments (grant recipients)
• public health advocacy organizations (potential awareness campaign contractors)

Named in the bill

Department of Health and Human Services (HHS), National Institute of Environmental Health Sciences (NIEHS), Food and Drug Administration (FDA), State health departments, Indian Tribes and Tribal organizations, WPM (Wheaton Precious Metals — mapped regulatory exposure), TSN (Tyson Foods — mapped regulatory exposure), BALL (Ball Corporation — mapped regulatory exposure), TGT (Target — mapped regulatory exposure), AMCR (Amcor — mapped regulatory exposure)

Where it stands

3 cosponsors: 3 Democrats.

• Jun 5, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 5, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,514,644 in lobbying spend. A filing names 19 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Shontel Brown, the sponsor, reported $771,344 in PAC receipts in the 2026 cycle.

• Real Estate Roundtable — $1,484,644 on 1 filing
• Real Estate Roundtable — $30,000 on 1 filing

Lobbying Disclosure Act filings through Jul 19, 2026. A filing shows who paid to lobby on a bill it names, not what changed.